Index to Volume 24

Author Index

-A-

Abarca J, Malone DC, Armstrong EP, Zachry III WM: Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Heart Failure Enrolled in a Managed Care Organization: Effect on Costs and Probability of Hospitalization, 351

Abdolell M: see Dupuis LL, et al, 564

ACCP, Calis KA, Hutchison LC, Elliott ME, Ives TJ, Zillich AJ, Poirier T, Townsend KA, Woodall B, Feldman S, Raebel MA: Healthy People 2010: Challenges, Opportunities, and a Call to Action for America's Pharmacists, 1241

ACCP: Annual Meeting 2004 Abstracts and Index of Authors, 1419

Adams MP, Ahdieh H: Pharmacokinetics and Dose-Proportionality of Oxymorphone Extended Release and Its Metabolites: Results of a Randomized Crossover Study, 468

Adkins LM: see Kim KY, et al, 419

Agarwal R, Vasavada N, Chase SD: Evaluation of Kidney Function in Patients with Acute Renal Failure Using High-Performance Liquid Chromatography: A Case Report, 145

Agboola O: see Cosler LE, et al, 488

Ahdieh H: see Adams MP, et al, 468

Ait-Daoud N: see Lam YWF, et al, 477

Akers WS, Flynn JD, Davis GA, Green AE, Winstead PS, Strobel G: Prolonged Cardiac Repolarization After Tacrolimus and Haloperidol Administration in the Critically Ill Patient, 404

Akers WS: see Flynn JD, et al, 930

Albano D: see Grothe DR, et al, 621

Albert M: see Williamson DR, et al, 409

Alexander B: see Bishop JR, et al, 515

Alexander E, Susla GM, Burstein AH, Brown DT, Ognibene FP: Retrospective Evaluation of Commonly Used Equations to Predict Energy Expenditure in Mechanically Ventilated, Critically Ill Patients, 1659

Allen MJ: see Sketris IS, et al, 784

Allen U: see Dupuis LL, et al, 564

Alley JL: see Thames WA, et al, 313

Andersen J: see Dager WE, et al, 88S

Anderson Jr HG: see McCall KL, et al, 188

Andrus MR: Oral Anticoagulant Drug Interactions with Statins: Case Report of Fluvastatin and Review of the Literature, 285

Angood PB: see Yogarantnam D, et al, 1793

Ansara AJ: see Dobesh PP, et al, 1554

Ansell J: see Nutescu EA, et al, 1204

Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA: Comparison of Cytochrome P450 2C9 Genotyping Methods and Implications for the Clinical Laboratory, 720

Archer SM: see Davis GA, et al, 26

Argo TR, Carnahan RM, Perry PJ: Aripiprazole, a Novel Atypical Antipsychotic Drug, 212

Armstrong EP: see Abarca J, et al, 351

Arouni AJ: see Packard KA, et al, 546

Asmus MJ, Liang J, Coowanitwong I, Hochhaus G: In Vitro Performance Characteristics of Valved Holding Chamber and Spacer Devices with a Fluticasone Metered-Dose Inhaler, 159

-B-

Badawi O, Oyen LJ, Haines ST: Dosing of Unfractionated Heparin in Acute Coronary Syndromes, 1681

Badger NO, Butler K, Hallman LC: Excessive Anticoagulation and Anaphylactic Reaction After Rechallenge with Lepirudin in a Patient with Heparin-Induced Thrombocytopenia, 1800

Bagheri H, Fouladi A, Barange K, Lapeyre-Mestre M, Payen JL, Montastruc JL, Vinel JP: Follow-up of Adverse Drug Reactions from Peginterferon alfa-2b-Ribavirin Therapy, 1546

Bailie GR: From Dialysis Outcomes Quality Initiative to Kidney Disease Outcomes Quality Initiative: New Clinical Practice Guidelines in Nephrology-What the Practicing Pharmacist Needs to Know, 551

Baird TK: see Hall LG, et al, 1002

Bajjoka I: see Corpus K, et al, 1084

Baker SD: see Rudek MA, et al, 16

Bakst G: see Stroup J, et al, 736

Barange K: see Bagheri H, et al, 1546

Bard RL, Bleske BE, Nicklas JM: Food: An Unrecognized Source of Loop Diuretic Resistance, 630

Barner JC, Worchel J, Yang M: Frequency of New-Onset Diabetes Mellitus and Use of Antipsychotic Drugs Among Central Texas Veterans, 1529

Baroletti SA, Wahlstrom HD: Interaction Between Nesiritide and a Heparin-Coated Pulmonary Artery Line During an Infusion for Decompensated Heart Failure, 1634

Baroletti SA: see Gabardi S, et al, 1323

Bartt RE: see Chong PH, et al, 1194

Bates CM: see Robinson RF, et al, 195

Batisky DL: see Robinson RF, et al, 195

Batra VK: see Rudek MA, et al, 16

Bauman JL: see Nutescu EA, et al, 165S

Bauman JL: Tales of Two Oral Anticoagulants from Natural Product Research and Their Impact on Clinical Pharmacy, 166S

Beckey NP: see Parra D, et al, 987

Beddingfield JJ: see Reeves RR, et al, 1804

Beitelshees AL: see Larisa H, et al, 750

Bélanger C: see LeBlanc M, et al, 924

Bell D: see Dobesh PP, et al, 105
Berenson CS: see Smith PF, et al, 970
Berenson CS: see Smith PF, et al, 1508
Bestul DJ: see Obritsch MD, et al, 1050
Bestul MB, McCollum M, Hansen LB, Saseen JJ: Impact of the Women's Health Initiative Trial Results on Hormone Replacement Therapy, 495
Bestul MB, McCollum M, Stringer KA, Burchenal J: Impact of a Critical Pathway on Acute Myocardial Infarction Quality Indicators, 173
Bhanji NH, Margolese HC: Extrapyramidal Symptoms Related to Adjunctive Nizatidine Therapy in an Adolescent Receiving Quetiapine and Paroxetine, 921
Biery JC: see Marceille JR, et al, 1317
Bigelow GE: see Hendrix CW, et al, 1110
Biggs RS: see Simpson SH, et al, 389
Bishop JR, Alexander B, Lund BC, Klepser TB: Osteoporosis Screening and Treatment in Women with Schizophrenia: A Controlled Study, 515
Bizien MD, Jue SG, Panning C, Cusack B, Peterson T: Blood Pressure Control and Factors Predicting Control in a Treatment-Compliant Male Veteran Population, 179
Blackburn JC: see Nutescu EA, et al, 1204
Blaxill MF: Study Fails To Establish Diagnostic Substitution as a Factor in Increased Rate of Autism, 812
Bleske BE: see Bard RL, et al, 630
Blevins S: see Ripley TL, et al, 1638
Block JH: see Brackett CC, et al, 854
Bloom K: see Mixides G, et al, 291
Boccuzzi SJ: see Wittkowsky AK, et al, 1668
Boehme S, Wilson DB: Amifostine-Induced Fever: Case Report and Review of the Literature, 155
Bond CA, Raehl CL, Patry R: Evidence-Based Core Clinical Pharmacy Services in United States Hospitals in 2020: Services and Staffing, 427
Bond CA, Raehl CL, Patry R: The Feasibility of Implementing an Evidence-Based Core Set of Clinical Pharmacy Services in 2020: Manpower, Marketplace Factors, and Pharmacy Leadership, 441
Bond CA, Raehl CL: Pharmacist-Provided Anticoagulation Management in United States Hospitals: Death Rates, Length of Stay, Medicare Charges, Bleeding Complications, and Transfusions, 953
Booker BM: see Smith PF, et al, 970
Booker BM: see Smith PF, et al, 1508
Bornikova L: see Spyropoulos AC, et al, 649
Boskovich A: see Chong PH, et al, 1194
Bosso JA: Clinical Pharmacy and Pharmaceutical Care, 1499
Bosso JA: The Impact of Antibiotic Management on Resistance, 224S
Boulanger I: see Williamson DR, et al, 409
Brackett CC, Singh H, Block JH: Likelihood and Mechanisms of Cross-Allergenicity Between Sulfonamide Antibiotics and Other Drugs Containing a Sulfonamide Functional Group, 854
Bradberry JC: see Snella KA, et al, 372
Brennan DC: see Hardinger KL, et al, 1159
Brock S, Jennings HR: Fatal Acute Encephalomyelitis After a Single Dose of Intrathecal Methotrexate, 673
Brokaw DK: see Sicat BL, et al, 79
Brouse SD: see Dobesh PP, et al, 105
Brown DT: see Alexander E, et al, 1659
Bryowsky JJ, Bugnitz MC, Hak EB: Pamidronate Treatment for Hypercalcemia in an Infant Receiving Parenteral Nutrition, 937
Buchanan NN: see Murray MD, et al, 324
Buck ML: see Davenport JD, et al, 522
Bugnitz MC: see Bryowsky JJ, et al, 937
Bugnitz MC: see Crill CM, et al, 1130
Bullock JM: see Smith PF, et al, 970
Bullock JM: see Smith PF, et al, 1508
Burchenal J: see Bestul MB, et al, 173
Burleson BS, Ritchie DJ, Micek ST, Dunne WM: *Enterococcus faecalis* Resistant to Linezolid: Case Series and Review of the Literature, 1225
Burstein AH: see Alexander E, et al, 1659
Busch RS: see Stroup J, et al, 736
Bussey H, Francis JL: Heparin Overview and Issues, 103S
Bussey HI: Blood, Sweat, and Tears: Wasted by Medicare's Missed Opportunity, 1655
Bussey HI: see Busti AJ, et al, 184S
Bussey HI: see Nutescu EA, et al, 199S
Busti AJ, Bussey HI: The Role of Oral Direct Thrombin Inhibitors in the Treatment of Venous Thromboembolism, 184S
Busti AJ, Hall II RG, Margolis DM: Atazanavir for the Treatment of Human Immunodeficiency Virus Infection, 1732
Busti AJ, Murillo Jr JR, Cryer B: Tegaserod-Induced Myocardial Infarction: Case Report and Hypothesis, 526
Butler K: see Badger NO, et al, 1800
Byers KE: see Capitano B, et al, 803

-C-

Cady PS: see Wilkingson JJ, et al, 978
Cady R: see Wenzel R, et al, 638
Calhoun EA: see Cosler LE, et al, 488
Calis KA: see ACCP, et al, 1241
Callahan BL: see Prescott Jr WA, et al, 532
Capitano B, Nicolau DP, Potoski BA, Byers KE, Horowitz M, Venkataramanan R, Paterson DL: Meropenem Administered as a Prolonged Infusion to Treat Serious Gram-Negative Central Nervous System Infections, 803
Carleton B: see Etminan M, et al, 338
Carnahan RM: see Argo TR, et al, 212
Carnes CA, Pickworth KK, Votolato NA, Raman SV: Elevated Defibrillation Threshold with Venlafaxine Therapy, 1095
Caron MF: see Reddy P, et al, 1013
Carroll DG, Kline KM, Malnar KF: Role of Topiramate for the Treatment of Painful Diabetic Peripheral Neuropathy, 1186
Carson SW, Letrent KJ, Kotlyar M, Foose G, Tancer

ME: Lack of a Fluoxetine Effect on Prednisolone Disposition and Cortisol Suppression, 482
Carter O: see Ng TMH, et al, 1594
Carver PL: see DePestel DD, et al, 1539
Cavallari LH: see Larisa H, et al, 750
Cavanaugh SE: see Scheife RT, et al, 821
Cha SS: see Hall LG, et al, 1002
Chandraker AK: see Gabardi S, et al, 1323
Chang CM, Liu PYY, Yang YHK, Yang YC, Wu CF, Lu FH: Potentially Inappropriate Drug Prescribing Among First-Visit Elderly Outpatients in Taiwan, 846
Chant C: see Chin TWF, et al, 705
Chase SD: see Agarwal R, et al, 145
Cheng JWM, Frank L, Garrett SD, Lu Y, Sanoski CA, White CM: Key Articles and Guidelines in Pharmacotherapeutic Management of Arrhythmias, 248
Chin CM, Gutierrez M, Still JG, Kosutic G: Pharmacokinetics of Modified Oral Calcitonin Product in Healthy Volunteers, 994
Chin TWF, Chant C, Tanzini R, Wells J: Severe Acute Respiratory Syndrome (SARS): The Pharmacist's Role, 705
Chong PH, Boskovich A, Stevkovic N, Bartt RE: Statin-Associated Peripheral Neuropathy: Review of the Literature, 1194
Christman AK, Fermo JD, Markowitz JS: Atomoxetine, a Novel Treatment for Attention-Deficit-Hyperactivity Disorder, 1020
Christopher J: see Hendrix CW, et al, 1110
Cina JL: see Gabardi S, et al, 1323
Cinti SK: see DePestel DD, et al, 1539
Cloen D: see Smith PF, et al, 970
Coakley DF: see Smith PF, et al, 970
Cohen BM: see Gören JL, et al, 1501
Coleman CI, Perkerson KA, Lewis A: Alendronate-Induced Auditory Hallucinations and Visual Disturbances, 799
Coleman CI: see Reddy P, et al, 1013
Condren ME: see Gaylor AS, et al, 869
Cooper JV: see McBurney CR, et al, 1515
Coowanitwong I: see Asmus MJ, et al, 159
Corpus K, Hegeman-Dingle R, Bajjoka I: *Candida kefyr*, an Uncommon but Emerging Fungal Pathogen: Report of Two Cases, 1084
Cosler LE, Calhoun EA, Agboola O, Lyman GH: Effects of Indirect and Additional Direct Costs on the Risk Threshold for Prophylaxis with Colony-Stimulating Factors in Patients at Risk for Severe Neutropenia from Cancer Chemotherapy, 488
Cossette P: see LeBlanc M, et al, 924
Courval M, Palisaitis DA, Diodati JG, Lesperance B, Pharand C: Inhibition of Streptokinase-Induced, Antibody-Mediated Platelet Aggregation with Tirofiban After Exposure to Streptokinase or Streptococcal Infection, 558
Cox CD: see Tsikouris JP, et al, 1154
Crill CM, Bugnitz MC, Hak EB: Evaluation of Gastric pH and Guaiac Measurements in Neonates Receiving Acid Suppression Therapy During Extracorporeal Membrane Oxygenation, 1130
Crismon ML: see Patel NC, et al, 822
Cryer B: see Busti AJ, et al, 526
Cudd LA: see Fugate SE, et al, 1213
Culkin D: see Ripley TL, et al, 1638
Cullinane DC: see Hall LG, et al, 1002
Cusack B: see Bizien MD, et al, 179
Cutler DL: see Rudek MA, et al, 16

-D-

Dager WE, Andersen J, Nutescu EA: Special Considerations with Fondaparinux Therapy: Heparin-Induced Thrombocytopenia and Wound Healing, 88S
Dager WE, Gosselin RC, Owings JT: Argatroban Therapy for Antithrombin Deficiency and Mesenteric Thrombosis: Case Report and Review of the Literature, 659
Dager WE: see Dobesh PP, et al, 105
Dager WE: see Nutescu EA, et al, 199S
Dahl NV: see Seligman PA, et al, 574
Daly DE: see Dobesh PP, et al, 105
Damico KE: see Gören JL, et al, 1501
Danehower SC: see Ruane PJ, et al, 307
Dasta JF: see Rudis MI, et al, 229
Davenport JD, McCarthy MW, Buck ML: Excessive Somnolence from Aripiprazole in a Child, 522
Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ: Effect of Fluticasone Propionate Nasal Spray on Bioavailability of Intranasal Hydromorphone Hydrochloride in Patients with Allergic Rhinitis, 26
Davis GA: see Akers WS, et al, 404
de Denus S, Hardy AM, Olson KL, Robinette B: Key Articles and Guidelines in the Management of Hypertension, 1385
de Denus S, Spinler SA, Jessup M, Kao A: History of Depression as a Predictor of Adverse Outcomes in Patients Hospitalized for Decompensated Heart Failure, 1306
de Denus S, Spinler SA, Miller K, Peterson AM: Statins and Liver Toxicity: A Meta-Analysis, 584
De Shong D, Mathis AS: Lessons in Formulary Management: The Case of Fenoldopam for Radiographic Contrast Material-Induced Nephropathy, 819
Deitelzweig S, Groce III JB: Anticoagulant Prophylaxis in Medical Patients: An Objective Assessment, 120S
DeJesus E: see Ruane PJ, et al, 307
Delaney JAC: see Etminan M, et al, 338
Dennis E: see Pfannkuche HJ, et al, 1649
DePestel DD, Kazanjian PH, Cinti SK, Kauffman CA, Carver PL: Magnitude and Duration of Elevated Gastric pH in Patients Infected with Human Immunodeficiency Virus After Administration of Chewable, Dispersible, Buffered Didanosine Tablets, 1539
DeSilva KE: see Guest JL, et al, 727
Devine EB: see Wittkowsky AK, et al, 1311
Devine EB: see Wittkowsky AK, et al, 600
Diamond S: see Wenzel R, et al, 638

Diaz-Linares M: see Pai MP, et al, 592
Dickerson LM: see Ornstein SM, et al, 500
Díez J: see Rihn TL, et al, 132S
Diodati JG: see Courval M, et al, 558
Dobesh PP, Brouse SD, Johnson DC, Dager WE, Bell D, Daly DE, Olin JL, Wodlinger AM: Key Articles and Guidelines Relative to Treatment of Patients with Acute Coronary Syndromes, 105
Dobesh PP, Stacy ZA, Ansara AJ, Enders JM: Drug-Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease, 1554
Dobesh PP: Economics of Unfractionated Heparin: Beyond Acquisition Cost, 161S
Dobesh PP: Evidence for Extended Prophylaxis in the Setting of Orthopedic Surgery, 73S
Dobesh PP: Unfractionated Heparin Dosing Nomograms: Road Maps to Where?, 142S
Dobesh PP: Ximelagatran: Pharmacology, Pharmacokinetics, and Pharmacodynamics, 169S
Doe NS: see Longstreth KL, et al, 808
Donehower RC: see Rudek MA, et al, 16
Doraiswamy PM: see Szarfman A, et al, 1099
Dortch M: see Wenzel R, et al, 638
Dougherty R: see Friedrich LV, et al, 1807
Doyle J: see Dupuis LL, et al, 564
Drake E: see Lalonde L, et al, 907
Dressler RM: see James CW, et al, 415
Drew RH: Key References in Infectious Diseases Pharmacotherapy, 1586
Dubisar BM, Stoner SC, Reynolds J, Khan R, Ramlatchman L: Adverse Effects of Atypical Antipsychotic Agents and Their Effects on Quality of Life, 841
Dubisar BM: see Stoner SC, et al, 1147
Ducharme MP: see Seligman PA, et al, 574
Duguay P: see Lalonde L, et al, 907
Dunlap SH: see Larisa H, et al, 750
Dunne WM: see Burleson BS, et al, 1225
Dupuis LL, Sung L, Taylor T, Abdolell M, Allen U, Doyle J, Taddio A: Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once-Daily versus Thrice-Daily Administration, 564
Dzikowski AL: see Shrader SP, et al, 943

-E-

Eagle KA: see McBurney CR, et al, 1515
Eckert GJ: see Murray MD, et al, 324
Eddy TD: see Kennedy DT, et al, 1400
Egorin MJ: see Ramalingam S, et al, 1232
Elliott ME: see ACCP, et al, 1241
Enders JM: see Dobesh PP, et al, 1554
Epstein BJ: Elevations in Serum Creatinine Concentration: Concerning or Reassuring?, 697
Erickson SR, Williams BC, Gruppen LD: Relationship Between Symptoms and Health-Related Quality of Life in Patients Treated for Hypertension, 344
Erickson SR: see McBurney CR, et al, 1515
Etminan M, Carleton B, Delaney JAC, Padwal R: Macrolide Therapy for *Chlamydia pneumoniae* in the Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials, 338
Etminan M, Samii A: Pharmacoepidemiology I: A Review of Pharmacoepidemiologic Study Designs, 964
Etminan M: Pharmacoepidemiology II: The Nested Case-Control Study-A Novel Approach in Pharmacoepidemiologic Research, 1105
Everts RJ, Hayhurst MD, Nona BP: Acute Pulmonary Edema Caused by Quinine, 1221

-F-

Fashingbauer LA: see Larisa H, et al, 750
Faulkner MA: see Hilleman DE, et al, 1077
Feldman S: see ACCP, et al, 1241
Fermo JD: see Christman AK, et al, 1020
Fermo JD: see Shrader SP, et al, 943
Fincher TK: see Gubbins PO, et al, 460
Finley R: see Lee KC, et al, 401
Fish DN: see Obritsch MD, et al, 1050
Fitzsimons MG, Gaudette RR, Hurford WE: Critical Rebound Methemoglobinemia After Methylene Blue Treatment: Case Report, 538
Flaherty JF: see Smith PF, et al, 970
Fleming MF: see Mundt MP, et al, 829
Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K: Pharmacokinetic Characteristics of Ritonavir, Zidovudine, Lamivudine, and Stavudine in Children with Human Immunodeficiency Virus Infection, 453
Florea NR: see Kuti JL, et al, 8
Flynn JD, Akers WS, Jones M, Stevkovic N, Waid T, Mullett T, Jahania S: Treatment of Respiratory Syncytial Virus Pneumonia in a Lung Transplant Recipient: Case Report and Review of the Literature, 930
Flynn JD: see Akers WS, et al, 404
Fontes CL: see Yu-Isenberg KS, et al, 33
Foose G: see Carson SW, et al, 482
Foote EF, Lin AYF: Pharmacy Education: Back to the Basics?—An Alternative Viewpoint, 685
Foral PA: see Lenz TL, et al, 1137
Force RW: see Wilkingson JJ, et al, 978
Fouladi A: see Bagheri H, et al, 1546
Frail DM: see Sketris IS, et al, 784
Francis JL, Groce III JB: Challenges in Variation and Responsiveness of Unfractionated Heparin, 108S
Francis JL: see Bussey HI, et al, 103S
Francis JL: see Niccolai CS, et al, 146S
Frangos SG: Transfusion Trigger: A Careless Term That Disregards Pathophysiology, 948
Frank L: see Cheng JWM, et al, 248
Franks AM: see Gubbins PO, et al, 460
Fraser GL: see Owens Jr RC, et al, 894
Freshley A: see Lindsey CC, et al, 167
Friedrich LV, Dougherty R: Fatal Hypoglycemia Associated with Levofloxacin, 1807
Fuchs EJ: see Hendrix CW, et al, 1110
Fugate SE, Nichols CM, Cudd LA: Impaired Warfarin

Response Secondary to High-Dose Vitamin K_1 for Rapid Anticoagulation Reversal: Case Series and Literature Review, 1213
Fung HB: see Guo Y, et al, 1084

-G-

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK: Efficacy and Safety of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Renal Transplant Recipients: A Single-Center, Retrospective Analysis, 1323
Gabay M: see Mancuso CE, et al, 1177
Gandhi PJ: see Yogarantnam D, et al, 1793
Gannon JM: see Packard KA, et al, 546
Garrett SD: see Cheng JWM, et al, 248
Gaudette RR: see Fitzsimons MG, et al, 538
Gaylor AS, Condren ME: Type 2 Diabetes Mellitus in the Pediatric Population, 869
Gebhart B, Jorgenson JA: Benefit of Ribose in a Patient with Fibromyalgia, 1646
Geissler EC: see Yu-Isenberg KS, et al, 33
Genina VY: see Kennedy DT, et al, 1400
Gershovich OE, Lyman Jr AE: Liver Function Test Abnormalities and Pruritus in a Patient Treated with Atorvastatin: Case Report and Review of the Literature, 150
Giffin SA: see Thames WA, et al, 313
Goins JA: see Marceille JR, et al, 1317
Goldberg ME: see Larijani GE, et al, 1675
Goldspiel BR: Chemotherapy Dose Density in Early-Stage Breast Cancer and Non-Hodgkin's Lymphoma, 1347
Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM: Bioavailability and Lack of Toxicity of S-Adenosyl-L-Methionine (SAMe) in Humans, 1501
Gosselin RC: see Dager WE, et al, 659
Gracia R, Shepherd G: Cyanide Poisoning and Its Treatment, 1358
Graham MR: see Lindsey CC, et al, 167
Gratz I: see Larijani GE, et al, 1675
Green AE: see Akers WS, et al, 404
Greene RS: see Irons BK, et al, 362
Grégoire G: see Williamson DR, et al, 409
Gregory A: see Sharp RP, et al, 1236
Griffin EN: see Kennedy DT, et al, 1400
Groce III JB: see Deitelzweig S, et al, 120S
Groce III JB: see Francis JL, et al, 108S
Groo VL: see Larisa H, et al, 750
Grothe DR, Scheckner B, Albano D: Treatment of Pain Syndromes with Venlafaxine, 621
Grover SA: see Lalonde L, et al, 907
Gruppen LD: see Erickson SR, et al, 344
Guay DRP: Oritavancin and Tigecycline: Investigational Antimicrobials for Multidrug-Resistant Bacteria, 58
Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, Penzak SR, Saccente M: Influence of Grapefruit Juice on the Systemic Availability of Itraconazole Oral Solution in Healthy Adult Volunteers, 460
Guest JL, Ruffin C, Tschampa JM, DeSilva KE, Rimland D: Differences in Rates of Diarrhea in Patients with Human Immunodeficiency Virus Receiving Lopinavir-Ritonavir or Nelfinavir, 727
Guillaume M: see Thébault JJ, et al, 1295
Guillory GS: see Manor SM, et al, 664
Guillory GS: see Ng TMH, et al, 1594
Guo Y, Fung HB: Fatal Lactic Acidosis Associated with Coadministration of Didanosine and Tenofovir Disoproxil Fumarate, 1089
Gurley BJ: see Gubbins PO, et al, 460
Gutierrez M: see Chin CM, et al, 994

-H-

Haas CE: see Smith PF, et al, 970
Haas CE: see Smith PF, et al, 1508
Haider S: see Stephens JM, et al, 1714
Haines ST: see Badawi O, et al, 1681
Hak EB: see Crill CM, et al, 1130
Hak EB: see Bryowsky JJ, et al, 937
Hall II RG: see Busti AJ, et al, 1732
Hall LG, Oyen LJ, Taner CB, Cullinane DC, Baird TK, Cha SS, Sawyer MD: Fixed-Dose Vasopressin Compared with Titrated Dopamine and Norepinephrine as Initial Vasopressor Therapy for Septic Shock, 1002
Hallman LC: see Badger NO, et al, 1800
Hamilton RA: see Stroup J, et al, 736
Hansen LB: see Bestul MB, et al, 495
Hansen LB: see Snella KA, et al, 372
Harada ASM: see Yu-Isenberg KS, et al, 33
Hardinger KL, Koch MJ, Brennan DC: Current and Future Immunosuppressive Strategies in Renal Transplantation, 1159
Hardy AM: see de Denus S, et al, 1385
Hardy H, Skolnik PR: Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus Infection, 198
Harris LE: see Murray MD, et al, 324
Hartnell NR, Wilson JP: Replication of the Weber Effect Using Postmarketing Adverse Event Reports Voluntarily Submitted to the United States Food and Drug Administration, 743
Hassan E: see Rudis MI, et al, 229
Hauben M: Application of an Empiric Bayesian Data Mining Algorithm to Reports of Pancreatitis Associated with Atypical Antipsychotics, 1122
Hauch O: see Wittkowsky AK, et al, 1668
Havranek EP: see Krantz MJ, et al, 768
Havrda DE: see Ripley TL, et al, 1638
Hawkins D: Limitations of Traditional Anticoagulants, 62S
Hawkins D: Pharmacoeconomics of Thrombosis Management, 95S
Hawkins D: The Role of Oral Direct Thrombin Inhibitors in the Prophylaxis of Venous Thromboembolism, 179S
Hayes JR: see Robinson RF, et al, 195
Hayes MJ: see Ramalingam S, et al, 1232
Hayhurst MD: see Everts RJ, et al, 1221
Haynes DK: see Krantz MJ, et al, 768

Hegeman-Dingle R: see Corpus K, et al, 1084
Helgason CM: see Nutescu EA, et al, 82S
Hemstreet BA: Evaluation of Carvedilol for the Treatment of Portal Hypertension, 94
Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, Christopher J, Fuchs EJ, Snidow JW: Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Amprenavir in Opioid-Dependent Subjects, 1110
Hepler CD: Clinical Pharmacy, Pharmaceutical Care, and the Quality of Drug Therapy, 1491
Hicks RW: see Niccolai CS, et al, 146S
Hilleman DE, Faulkner MA, Monaghan MS: Cost of a Pharmacist-Directed Intervention to Increase Treatment of Hypercholesterolemia, 1077
Hilleman DE, Lucas Jr BD: Angiotensin-Converting Enzyme Inhibitors and Stroke Risk: Benefit Beyond Blood Pressure Reduction?, 1064
Hilleman DE: see Lenz TL, et al, 1137
Hilleman DE: see Packard KA, et al, 546
Hill-Zabala CE: see Ruane PJ, et al, 307
Hochhaus G: see Asmus MJ, et al, 159
Hodges B, Mazur JE: Intravenous Ethanol for the Treatment of Alcohol Withdrawal Syndrome in Critically Ill Patients, 1578
Holdford DA: see Kennedy DT, et al, 1400
Horowitz M: see Capitano B, et al, 803
Horowitz S: see Reddy P, et al, 1013
How PP, Lau AH: Malnutrition in Patients Undergoing Hemodialysis: Is Intradialytic Parenteral Nutrition the Answer?, 1748
Howard PA: see Ng TMH, et al, 1594
Huber M: see Niederhofer H, et al, 1524
Hunter CB: see Lenz TL, et al, 1137
Hurford WE: see Fitzsimons MG, et al, 538
Hutchison LC: see ACCP, et al, 1241

-I, J-

Irons BK, Mazzolini TA, Greene RS: Delaying the Onset of Type 2 Diabetes Mellitus in Patients with Prediabetes, 362
Ives TJ: see ACCP, et al, 1241
Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M: Steroid-Induced Diabetes Mellitus and Related Risk Factors in Patients with Neurologic Diseases, 508
Jacobi J: see Rudis MI, et al, 229
Jahania S: see Flynn JD, et al, 930
Jain SP: see Manor SM, et al, 664
James CW, Steinhaus MC, Szabo S, Dressler RM: Tenofovir-Related Nephrotoxicity: Case Report and Review of the Literature, 415
James EB: see Patel NC, et al, 822
Jann MW: Implications for Atypical Antipsychotics in the Treatment of Schizophrenia: Neurocognition Effects and a Neuroprotective Hypothesis, 1759
Javors MA: see Lam YWF, et al, 477
Jenkins P: see Spyropoulos AC, et al, 649
Jennings HR: see Brock S, et al, 673
Jennings HR: see Poston SA, et al, 668
Jessup M: see de Denus S, et al, 1306
Johnson BA: see Lam YWF, et al, 477
Johnson DC: see Dobesh PP, et al, 105
Johnson J: see Ruane PJ, et al, 307
Johnson JA: see Simpson SH, et al, 389
Johnson JA: see Aquilante CL, et al, 720
Johnston TP: see Lindsey CC, et al, 167
Jones AD: see McCall KL, et al, 188
Jones M: see Seligman PA, et al, 574
Jones M: see Flynn JD, et al, 930
Jorgenson JA: see Gebhart B, et al, 1646
Jue SG: see Bizien MD, et al, 179
Jung R: see Obritsch MD, et al, 1050
Jusko WJ: see Smith PF, et al, 1508

-K-

Kagawa Y: see Iwamoto T, et al, 508
Kalus JS: see Piotrowski AA, et al, 877
Kalus JS: see Reddy P, et al, 1013
Kane MP: see Stroup J, et al, 736
Kao A: see de Denus S, et al, 1306
Karapanos A: see Reddy P, et al, 1013
Kashyap ML: see Moon YSK, et al, 1692
Kauffman CA: see DePestel DD, et al, 1539
Ke V: see Kim KY, et al, 419
Kearney BP: see Smith PF, et al, 970
Kennedy DT, Paulson DM, Eddy TD, Patel PC, Patkar AD, Holdford DA, Genina VY, Griffin EN: A Smoking-Cessation Program Consisting of Extensive Counseling, Pharmacotherapy, and Office Spirometry: Results of a Pilot Project in a Veterans Administration Medical Center, 1400
Kennedy S: see Seifert CF, et al, 776
Kenyon KW: see Wittkowsky AK, et al, 190S
Kephart GC: see Sketris IS, et al, 784
Kerr JL, Oppelt TF, Rowen RC: Role of Clopidogrel in Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: From Literature and Guidelines to Practice, 1037
Khan R: see Dubisar BM, et al, 841
Kim KY, Ke V, Adkins LM: Donepezil for Alcohol-Related Dementia: A Case Report, 419
Kimko HC: see Seligman PA, et al, 574
Kiroff CG: see Lindsey CC, et al, 167
Kistler JS: see Patel NC, et al, 822
Klepser TB: see Bishop JR, et al, 515
Kline KM: see Carroll DG, et al, 1186
Kline-Rogers EM: see McBurney CR, et al, 1515
Kluger JK: see Reddy P, et al, 1013
Knauft RF: see Kuti JL, et al, 1641
Koch MJ: see Hardinger KL, et al, 1159
Kojima M: see Iwamoto T, et al, 508
Korytkowski MT: Sulfonylurea Treatment of Type 2 Diabetes Mellitus: Focus on Glimepiride, 606
Kosutic G: see Chin CM, et al, 994
Kotlyar M: see Carson SW, et al, 482
Kotsanas D: see Lim LL, et al, 1652
Kovacs SJ: An Individual Perspective on the Pharmacy Education Scope of Practice Disconnect, 677

Krantz MJ, Havranek EP, Mehler PS, Haynes DK, Long CS: Impact of a Cardiac Risk Reduction Program in Vulnerable Patients Hospitalized with Coronary Artery Disease, 768
Krantz MJ: Angiotensin-Converting Enzyme Inhibitors and Stroke: Blood Pressure Reduction Is Major Determinant of Risk, 1813
Kraus CK: see Mundt MP, et al, 829
Kristeller JL, Sterns RH: Transient Diabetes Insipidus After Discontinuation of Therapeutic Vasopressin, 541
Kuti JL, Florea NR, Nightingale CH, Nicolau DP: Pharmacodynamics of Meropenem and Imipenem Against Enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*, 8
Kuti JL, Moss KM, Nicolau DP, Knauft RF: Empiric Treatment of Multidrug-Resistant *Burkholderia cepacia* Lung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy, 1641
Kuzuhara S: see Iwamoto T, et al, 508

-L-

Lagattuta TF: see Ramalingam S, et al, 1232
Lalonde L, O'Connor AM, Drake E, Duguay P, Lowensteyn I, Grover SA: Development and Preliminary Testing of a Patient Decision Aid to Assist Pharmaceutical Care in the Prevention of Cardiovascular Disease, 907
Lam YWF, Javors MA, Ait-Daoud N, Roache JD, Johnson BA: Relative Bioavailability of an Extemporaneous Ondansetron 4-mg Capsule Formulation versus Solution, 477
Langaee TY: see Aquilante CL, et al, 720
Lapeyre-Mestre M: see Bagheri H, et al, 1546
Larijani GE, Goldberg ME, Gratz I, Warshal DP: Analgesic and Hemodynamic Effects of a Single 7.5-mg Intravenous Dose of Morphine in Patients with Moderate-to-Severe Postoperative Pain, 1675
Larisa H. Cavallari LH, Fashingbauer LA, Beitelshees AL, Groo VL, Southworth MR, Viana MAG, Williams RE, Dunlap SH: Racial Differences in Patients' Potassium Concentrations During Spironolactone Therapy for Heart Failure, 750
Lau AH: see How PP, et al, 1748
Lea JW: see Stoner SC, et al, 1147
LeBlanc M, Bélanger C, Cossette P: Severe and Resistant Hypoglycemia Associated with Concomitant Gatifloxacin and Glyburide Therapy, 924
Lee CR: see Ng TMH, et al, 1594
Lee KC, Finley R, Miller B: Apraxia of Lid Opening: Dose-Dependent Response to Carbidopa-Levodopa, 401
Lee TA: see Marceille JR, et al, 1317
Legreid AM: see Parra D, et al, 987
Lenz TL, Foral PA, Malesker MA, Hunter CB, Hilleman DE: Impact of Nesiritide on Health Care Resource Utilization and Complications in Patients with Decompensated Heart Failure, 1137
Lesperance B: see Courval M, et al, 558
Letrent KJ: see Carson SW, et al, 482
Levy R: see Thébault JJ, et al, 1295
Lewis A: see Coleman CI, et al, 799
Liang J: see Asmus MJ, et al, 159
Liao Q: see Ruane PJ, et al, 307
Liaw S: see Smith PF, et al, 970
Liebl MG: see Mixides G, et al, 291
Liles EA: see Tofade TS, et al, 1412
Lim LL, Kotsanas D, Ostergaard L, Woolley I: The Use of Antibiotics as Secondary Prevention for Cardiac Events, 1652
Lin AYF : see Foote EF, et al, 685
Lindsey CC, Graham MR, Johnston TP, Kiroff CG, Freshley A: A Clinical Comparison of Calculated versus Direct Measurement of Low-Density Lipoprotein Cholesterol Level, 167
Liu PYY: see Chang CM, et al, 846
Lobmeyer MT: see Aquilante CL, et al, 720
Lobo BL: Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data, 66S
Loeb JM: see Sims JJ, et al, 1
Lofland JH: see Wenzel R, et al, 638
Long CS: see Krantz MJ, et al, 768
Longstreth KL, Robbins SD, Smavatkul C, Doe NS: Cephalexin-Induced Acute Tubular Necrosis, 808
Lou Y: see Hendrix CW, et al, 1110
Lowensteyn I: see Lalonde L, et al, 907
Lu FH: see Chang CM, et al, 846
Lu Y: see Cheng JWM, et al, 248
Lucas Jr BD: see Hilleman DE, et al, 1064
Lund BC: see Bishop JR, et al, 515
Lyman GH: see Cosler LE, et al, 488
Lyman Jr AE: see Gershovich OE, et al, 150
Lynch J, Wong-Beringer A: Caspofungin: A Potential Cause of Reversible Severe Thrombocytopenia, 1408

-M-

MacIntyre Jr NR: Chronic Obstructive Pulmonary Disease, 33S
Mack JE: see Reeves RR, et al, 1804
MacLaren R: see Obritsch MD, et al, 1050
Magee CC: see Gabardi S, et al, 1323
Mahan JD: see Robinson RF, et al, 195
Maine LL: Pharmacy Education Redux, 682
Makowsky M: see Wilbur K, et al, 1784
Malesker MA: see Lenz TL, et al, 1137
Malnar KF: see Carroll DG, et al, 1186
Malone DC: see Abarca J, et al, 351
Mancuso CE, Tanzi MG, Gabay M: Paradoxical Reactions to Benzodiazepines: Literature Review and Treatment Options, 1177
Manor SM, Guillory GS, Jain SP: Clopidogrel-Induced Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome After Coronary Artery Stenting, 664
Marceille JR, Goins JA, Soni R, Biery JC, Lee TA: Chronic Heart Failure–Related Interventions After Starting Rosiglitazone in Patients Receiving Insulin,

1317
Margolese HC: see Bhyanji NH, et al, 921
Margolis DM: see Busti AJ, et al, 1732
Marken PA: see Stoner SC, et al, 1147
Markowitz JS: see Christman AK, et al, 1020
Martin CP: see Tsikouris JP, et al, 1154
Martinez E: see Hendrix CW, et al, 1110
Mathis AS: see De Shong D, et al, 819
Mazur JE: see Hodges B, et al, 1578
Mazzolini TA: see Irons BK, et al, 362
McBride BF, White CM: Anemia Management in Heart Failure: A Thick Review of Thin Data, 757
McBurney CR, Eagle KA, Kline-Rogers EM, Cooper JV, Smith DE, Erickson SR: Work-Related Outcomes After a Myocardial Infarction, 1515
McCall KL, Anderson Jr HG, Jones AD: Determination of the Lack of a Drug Interaction Between Azithromycin and Warfarin, 188
McCarthy MW: see Davenport JD, et al, 522
McCollum M: see Bestul MB, et al, 173
McCollum M: see Bestul MB, et al, 495
McConnell SA: see Gubbins PO, et al, 460
McDonald CJ: see Murray MD, et al, 324
McIntosh K: see Fletcher CV, et al, 453
McNamara PJ: see Davis GA, et al, 26
Mehler PS: see Krantz MJ, et al, 768
Meyerrose GE: see Tsikouris JP, et al, 1154
Micek ST: see Burleson BS, et al, 1225
Middleton SC, Spencer AP: Assessment of Hypothyroidism in Patients with Chronic Heart Failure, 358
Miller B: see Lee KC, et al, 401
Miller K: see de Denus S, et al, 584
Mixides G, Liebl MG, Bloom K: Enteral Administration of Naloxone for Treatment of Opioid-Associated Intragastric Feeding Intolerance, 291
Monaghan MS: see Hilleman DE, et al, 1077
Montastruc JL: see Bagheri H, et al, 1546
Moon YSK, Kashyap ML: Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia, 1692
Moss KM: see Kuti JL, et al, 1641
Mowdy MH: see Sharp RP, et al, 1236
Mullett T: see Flynn JD, et al, 930
Mundt MP, Kraus CK, Fleming MF: Potential Drug Interactions with the Percent Carbohydrate-Deficient Transferrin (%CDT) Test, a New Alcohol Biomarker, 829
Munger MA: see Ng TMH, et al, 1594
Murillo Jr JR: see Busti AJ, et al, 526
Murray MD, Harris LE, Overhage JM, Zhou XH, Eckert GJ, Smith FE, Buchanan NN, Wolinsky FD, McDonald CJ, Tierney WM: Failure of Computerized Treatment Suggestions to Improve Health Outcomes of Outpatients with Uncomplicated Hypertension: Results of a Randomized Controlled Trial, 324

-N-

Nachman SA: see Fletcher CV, et al, 453
Nahata MC: see Robinson RF, et al, 195
Naito Y: see Iwamoto T, et al, 508
Neudeck BL: see Sims JJ, et al, 1
Ng TMH, Carter O, Guillory GS, Howard PA, Lee CR, Rodgers JE, Uber PA, Wiggins BS, Munger MA, Patterson JH: High-Impact Articles Related to the Pharmacotherapeutic Management of Systolic Heart Failure, 1594
Ng TMH: Levosimendan, a New Calcium-Sensitizing Inotrope for Heart Failure, 1366
Niccolai CS, Hicks RW, Oertel L, Francis JL: Unfractionated Heparin: Focus on a High-Alert Drug, 146S
Nichols CM: see Fugate SE, et al, 1213
Nicklas JM: see Bard RL, et al, 630
Nicolau DP: see Capitano B, et al, 803
Nicolau DP: see Kuti JL, et al, 1641
Nicolau DP: see Kuti JL, et al, 8
Niederhofer H, Huber M: Bupropion May Support Psychosocial Treatment of Nicotine-Dependent Adolescents: Preliminary Results, 1524
Nietert PJ: see Ornstein SM, et al, 500
Nightingale CH: see Kuti JL, et al, 8
Nona BP: see Everts RJ, et al, 1221
Novak RM: see Pai MP, et al, 592
Nutescu E, Singh-Khalsa M: Treatment of Venous Thromboembolism: Challenging the Unfractionated Heparin Standard, 127S
Nutescu E: see Wittkowsky AK, et al, 600
Nutescu EA, Bauman JL: New Developments in Anticoagulation Therapy: Oral Direct Thrombin Inhibitors, 165S
Nutescu EA, Helgason CM: Evolving Concepts in the Treatment of Venous Thromboembolism: The Role of Factor Xa Inhibitors, 82S
Nutescu EA, Pickard AS, Blackburn JC, Wittkowsky AK, Ansell J, Schumock GT: Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Clinics, 1204
Nutescu EA, Spinler SA, Dager WE, Bussey HI: Transitioning from Traditional to Novel Anticoagulants: The Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Management, 199S
Nutescu EA: Introduction-Current Concepts in Thrombosis Management: Focus on Factor Xa Inhibition, 61S
Nutescu EA: see Dager WE, et al, 88S

-O-

Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R: The Role of Vasopressin in Vasodilatory Septic Shock, 1050
O'Connor AM: see Lalonde L, et al, 907
Oertel LB: see Niccolai CS, et al, 146S
Oertel LB: Unfractionated Heparin: A Nursing Dilemma , 156S
Ognibene FP: see Alexander E, et al, 1659
Olin JL: see Dobesh PP, et al, 105
Olson KL: see de Denus S, et al, 1385
Oppelt TF: see Kerr JL, et al, 1037
Ornstein SM, Nietert PJ, Dickerson LM: Hypertension Management and Control in Primary Care: A Study of 20 Practices in 14 States, 500

Ostergaard L: see Lim LL, et al, 1652
Overhage JM: see Murray MD, et al, 324
Owens Jr RC, Fraser GL, Stogsdill P: Antimicrobial Stewardship Programs as a Means to Optimize Antimicrobial Use: Insights from the Society of Infectious Diseases Pharmacists, 894
Owings JT: see Dager WE, et al, 659
Oyen LJ: see Badawi O, et al, 1681
Oyen LJ: see Hall LG, et al, 1002

-P-

Packard KA, Arouni AJ, Hilleman DE, Gannon JM: Fingernail Clubbing and Chromonychia Associated with the Use of Angiotensin II Receptor Blockers, 546
Padwal R: see Etminan M, et al, 338
Pai MP, Schriever CA, Diaz-Linares M, Novak RM, Rodvold KA: Sex-Related Differences in the Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsules Boosted with Low-Dose Ritonavir in Patients Infected with Human Immunodeficiency Virus Type 1, 592
Pai MP: Pharmacy Education: Beyond the Basics, 690
Paladino JA: Economics of Antibiotic Use Policies, 232S
Palisaitis DA: see Courval M, et al, 558
Panning C: see Bizien MD, et al, 179
Park JM: see Prescott Jr WA, et al, 532
Parra D, Legreid AM, Beckey NP, Reyes S: Metformin Monitoring and Change in Serum Creatinine Levels in Patients Undergoing Radiologic Procedures Involving Administration of Intravenous Contrast Media, 987
Pashos CL: see Stephens JM, et al, 1714
Patel NC, Kistler JS, James EB, Crismon ML: A Retrospective Analysis of the Short-Term Effects of Olanzapine and Quetiapine on Weight and Body Mass Index in Children and Adolescents, 822
Patel P: see Wittkowsky AK, et al, 1668
Patel PC: see Kennedy DT, et al, 1400
Paterson DL: see Capitano B, et al, 803
Patkar AD: see Kennedy DT, et al, 1400
Patry R: see Bond CA, eet al, 427
Patry R: see Bond CA, et al, 441
Patterson JH: see Ng TMH, et al, 1594
Paulson DM: see Kennedy DT, et al, 1400
Payen JL: see Bagheri H, et al, 1546
Pelton S: see Fletcher CV, et al, 4
Penzak SR: see Gubbins PO, et al, 460
Perkerson KA: see Coleman CI, et al, 799
Perry PJ: see Argo TR, et al, 212
Peterson AM: see de Denus S, et al, 584
Peterson T: see Bizien MD, et al, 179
Pfannkuche HJ, Dennis E: Tegaserod-Induced Myocardial Infarction: Case Report and Hypothesis—An Alternative Viewpoint, 1649
Pharand C: see Courval M, et al, 558
Pickard AS: see Nutescu EA, et al, 1204
Pickworth KK: see Carnes CA, et al, 1095
Piotrowski AA, Kalus JS: Magnesium for the Treatment and Prevention of Atrial Tachyarrhythmias, 877
Pleasants II RA: Focus on Inhaled β_2-Agonists: Efficacy, Safety, and Patient Preference, 44S
Poe KL: see Poston SA, et al, 668
Poirier T: see ACCP, et al, 1241
Pomeroy CP: see Romanelli F, et al, 69
Poston SA, Jennings HR, Poe KL: Cefazolin Tolerance Does Not Predict Ceftriaxone Hypersensitivity: Unique Side Chains Precipitate Anaphylaxis, 668
Potoski BA: see Capitano B, et al, 803
Powell JR: Clinical Pharmacists Save Thousands of Lives: Big Decrease in Dose-Related Adverse Effects, 422
Powelson JA: see Gabardi S, et al, 1323
Prescott Jr WA, Callahan BL, Park JM: Tacrolimus Toxicity Associated with Concomitant Metoclopramide Therapy, 532

-Q, R-

Qaqish RB, Sims KA: Bone Disorders Associated with the Human Immunodeficiency Virus: Pathogenesis and Management, 1331
Raebel MA: see ACCP, et al, 1241
Raehl CL: see Bond CA, et al, 427
Raehl CL: see Bond CA, et al, 441
Raehl CL: see Bond CA, et al, 953
Ramalingam S, Lagattuta TF, Egorin MJ, Hayes MJ, Ramanathan RK: Biliary Excretion of Imatinib Mesylate and Its Metabolite CGP 74588 in Humans, 1232
Raman SV: see Carnes CA, et al, 1095
Ramanathan RK: see Ramalingam S, et al, 1232
Ramlatchman L: see Dubisar BM, et al, 841
Ramlatchman LV: see Stoner SC, et al, 1147
Rapp RP: Changing Strategies for the Management of Invasive Fungal Infections, 4S
Reddy P, Kalus JS, Caron MF, Horowitz S, Karapanos A, Coleman CI, Kluger JK, White CM: Economic Analysis of Intravenous Plus Oral Amiodarone, Atrial Septal Pacing, and Both Strategies to Prevent Atrial Fibrillation After Open Heart Surgery, 1013
Reeves RR, Beddingfield JJ, Mack JE: Carisoprodol Withdrawal Syndrome, 1804
Reyes S: see Parra D, et al, 987
Reynolds J: see Dubisar BM, et al, 841
Reynolds JB: see Stoner SC, et al, 1147
Richmond GJ: see Ruane PJ, et al, 307
Rihn TL, Díez J: Unfractionated Heparin in Cardiology: Redefining the Standard of Practice, 132S
Rimland D: see Guest JL, et al, 727
Ripley TL, Havrda DE, Blevins S, Culkin D: Early Evaluation of Hematuria in a Patient Receiving Anticoagulant Therapy and Detection of Malignancy, 1638
Ritchie DJ: see Burleson BS, et al, 1225
Roache JD: see Lam YWF, et al, 477
Robbins SD: see Longstreth KL, et al, 808
Robinette B: see de Denus S, et al, 1385
Robinson RF, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD: Effectiveness of Pretreatment in

Decreasing Adverse Events Associated with Pamidronate in Children and Adolescents, 195
Rodgers JE: see Ng TMH, et al, 1594
Rowen RC: see Kerr JL, et al, 1037
Rybak MJ: Resistance to Antimicrobial Agents: An Update, 203S

-S-

Samii A: see Etminan M, et al, 964
Sarmiento IA: see Gören JL, et al, 1501
Sawyer MD: see Hall LG, et al, 1002
Schumock GT: see Nutescu EA, et al, 1204
Sharp RP, Gregory A, Mowdy MH, Sirajuddin R: Nesiritide for Treatment of Heart Failure Due to Right Ventricular Dysfunction, 1236
Shepherd G: see Gracia R, et al, 1358
Sims KA: see Qaqish RB, et al, 1331
Singh-Khalsa M: see Nutescu E, et al, 127S
Sirajuddin R: see Sharp RP, et al, 1236
Smith BS: see Yogarantnam D, et al, 1793
Smith DE: see McBurney CR, et al, 1515
Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ: The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate, 1508
Smith PF, Kearney BP, Liaw S, Cloen D, Bullock JM, Haas CE, Yale K, Booker BM, Berenson CS, Coakley DF, Flaherty JF: Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R-, and S-Methadone, 970
Snidow JW: see Hendrix CW, et al, 1110
Soni R: see Marceille JR, et al, 1317
Spinler SA: see de Denus S, et al, 1306
Spinler SA: see Nutescu EA, et al, 199S
Stacy ZA: see Dobesh PP, et al, 1554
Stephens JM, Pashos CL, Haider S, Wong JM: Making Progress in the Management of Postoperative Pain: A Review of the Cyclooxygenase 2-Specific Inhibitors, 1714
Stevkovic N: see Chong PH, et al, 1194
Still JG: see Chin CM, et al, 994
Stoll AL: see Gören JL, et al, 1501
Stoner SC, Dubisar BM, Lea JW, Marken PA, Ramlatchman LV, Reynolds JB: Extended-Release Divalproex Sodium for Mood Stabilization, 1147
Suarez JA: see Tsikouris JP, et al, 1154
Susla GM: see Alexander E, et al, 1659
Szarfman A, Tonning JM, Doraiswamy PM: Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem, 1099

-T-

Taner CB: see Hall LG, et al, 1002
Tanzi MG: see Mancuso CE, et al, 1177
Thébault JJ, Guillaume M, Levy R: Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor, 1295
Tofade TS, Liles EA: Intentional Overdose with Insulin Glargine and Insulin Aspart, 1412
Tonning JM: see Szarfman A, et al, 1099
Townsend KA: see ACCP, et al, 1241
Tsikouris JP, Martin CP, Cox CD, Ziska M, Suarez JA, Meyerrose GE: Potential In Vitro Interaction Between Tenecteplase and Unfractionated Heparin, 1154

-U, V-

Uber PA: see Ng TMH, et al, 1594
Vanscoy GJ: The Inevitability of Change, 101S
Vinel JP: see Bagheri H, et al, 1546
Votolato NA: see Carnes CA, et al, 1095

-W-

Wahlstrom HD: see Baroletti SA, et al, 1634
Wakeford J: see Hendrix CW, et al, 1110
Warshal DP: see Larijani GE, et al, 1675
White CM: see Reddy P, et al, 1013
Wiggins BS: see Ng TMH, et al, 1594
Wilbur K, Makowsky M: Colchicine Myotoxicity: Case Reports and Literature Review, 1784
Wilkinson JJ, Force RW, Cady PS: Impact of Safety Warnings on Drug Utilization: Marketplace Life Span of Cisapride and Troglitazone, 978
Wire MB: see Hendrix CW, et al, 1110
Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O: Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs, 1668
Wittkowsky AK, Devine EB: Frequency and Causes of Overanticoagulation and Underanticoagulation in Patients Treated with Warfarin, 1311
Wittkowsky AK, Kenyon KW: The Role of Oral Direct Thrombin Inhibitors in Atrial Fibrillation, 190S
Wittkowsky AK: see Nutescu EA, et al, 1204
Wogen J: see Wittkowsky AK, et al, 1668
Wong JM: see Stephens JM, et al, 1714
Wong-Beringer A: see Lynch J, et al, 1408
Wong-Beringer A: Treating Serious Infections: Focus on Cefepime, 216S
Woodall B: see ACCP, et al, 1241
Woolley I: see Lim LL, et al, 1652
Worchel J: see Barner JC, et al, 1529
Wygant G: see Wittkowsky AK, et al, 1668

-Y, Z-

Yale K: see Smith PF, et al, 970
Yang M: see Barner JC, et al, 1529
Yogaratnam D, Smith BS, Angood PB, Gandhi PJ: Antifactor Xa Levels in Four Patients with Burn Injuries Who Received Enoxaparin to Prevent Venous Thromboembolism, 1793
Zillich AJ: see ACCP, et al, 1241
Ziska M: see Tsikouris JP, et al, 1154

Index to Volume 24

Subject Index

- A -

ACCP 2004 annual meeting, abstracts and index of authors, 1419

ACCP white paper, healthy people 2010: challenges, opportunities, and a call to action for America's pharmacists, 1241

ACE inhibitors and stroke: blood pressure reduction is major determinant of risk, 1813

Acetaminophen and ibuprofen, the antipyretic effect of, in children, 280

Acetaminophen intoxication and length of treatment: how long is long enough?—a comment, 694

Acid suppression therapy during extracorporeal membrane oxygenation, evaluation of gastric pH and guaiac measurements in neonates receiving, 1130

Acute coronary syndromes, dosing of unfractionated heparin in, 1681

Acute coronary syndromes, key articles and guidelines relative to treatment of patients with, 105

Acute myocardial infarction quality indicators, impact of a critical pathway on, 173

Acute tubular necrosis, cephalexin-induced, 808

Adverse effects of atypical antipsychotic agents and their effects on quality of life, 841

Alcohol biomarker, potential drug interactions with the percent carbohydrate-deficient transferrin (%CDT) test, a new, 829

Alcohol withdrawal syndrome, intravenous ethanol for the treatment of, in critically ill patients, 1578

Alcohol-related dementia, donepezil for: a case report, 419

Alendronate-induced auditory hallucinations and visual disturbances, 799

Amifostine-induced fever: case report and review of the literature, 155

Amiodarone, economic analysis of intravenous plus oral, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery, 1013

Amiodarone, intravenous, for conversion of atrial fibrillation: misled by meta-analysis?, 792

Amprenavir, pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with, in opioid-dependent subjects, 1110

Analgesic and hemodynamic effects of a single 7.5-mg intravenous dose of morphine in patients with moderate-to-severe postoperative pain, 1675

Anaphylactic reaction, excessive anticoagulation and, after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia, 1800

Anemia in the critically ill patient, managing, 229

Anemia management in heart failure: a thick review of thin data, 757

Angina, role of clopidogrel in unstable, and non–ST segment elevation myocardial infarction: from literature and guidelines to practice, 1037

Angiotensin II receptor blockers, fingernail clubbing and chromonychia associated with the use of, 546

Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization, 351

Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction, 1064

Angiotensin-converting enzyme inhibitors and stroke: blood pressure reduction is major determinant of risk, 1813

Antibiotic management, the impact of, on resistance, 224s

Antibiotic use policies, economics of, 232s

Antibiotics, the use of, as secondary prevention for cardiac events, 1652

Anticoagulant drug, oral, interactions with statins: case report of fluvastatin and review of the literature, 285

Anticoagulant prophylaxis in medical patients: an objective assessment, 120s

Anticoagulant therapy, early evaluation of hematuria in a patient receiving, and detection of malignancy, 1638

Anticoagulants, limitations of traditional, 62s

Anticoagulants, tales of two oral, from natural product research and their impact on clinical pharmacy, 166s

Anticoagulation clinics, impact of oral direct thrombin inhibitors on, 1204

Anticoagulation management, pharmacist-provided, in united states hospitals: death rates, length of stay, medicare charges, bleeding complications, and transfusions, 953

Anticoagulation management, transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on, 199s

Anticoagulation therapy, new developments in, oral direct thrombin inhibitors, 165s

Anticoagulation, excessive, and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia, 1800

Antifactor Xa activity, achieving target, with a heparin protocol based on sex, age, height, and weight, 713

Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism, 1793

Antimicrobial agents, resistance to, an update, 203s

Antimicrobial stewardship programs as a means to optimize antimicrobial use, 894

Antipsychotic drugs, frequency of new-onset diabetes

mellitus and use of, among central Texas veterans, 1529
Antipyretic effect of ibuprofen and acetaminophen in children, 280
Antithrombin deficiency and mesenteric thrombosis, argatroban therapy for: case report and review of the literature, 659
Apraxia of lid opening: dose-dependent response to carbidopa-levodopa, 401
Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction, 409
Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: case report and review of the literature, 659
Aripiprazole, a novel atypical antipsychotic drug, 212
Aripiprazole, excessive somnolence from, in a child, 522
Arrhythmias, key articles and guidelines in pharmacotherapeutic management of, 248
Atazanavir for the treatment of human immunodeficiency virus infection, 1732
Atomoxetine, a novel treatment for attention-deficit–hyperactivity disorder, 1020
Atorvastatin, liver function test abnormalities and pruritus in a patient treated with: case report and review of the literature, 150
Atrial fibrillation after open heart surgery, economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent, 1013
Atrial fibrillation, intravenous amiodarone for conversion of: misled by meta-analysis?, 792
Atrial fibrillation, the role of oral direct thrombin inhibitors in, 190s
Atrial septal pacing, economic analysis of intravenous plus oral amiodarone, and both strategies to prevent atrial fibrillation after open heart surgery, 1013
Atrial tachyarrhythmias, magnesium for the treatment and prevention of, 877
Attention-deficit–hyperactivity disorder, atomoxetine, a novel treatment for, 1020
Atypical antipsychotic agents, adverse effects of, and their effects on quality of life, 841
Atypical antipsychotics in the treatment of schizophrenia, implications for, neurocognition effects and a neuroprotective hypothesis, 1759
Atypical antipsychotics, application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with, 1122
Auditory hallucinations and visual disturbances, alendronate-induced, 799
Autism, study fails to establish diagnostic substitution as a factor in increased rate of (alternative viewpoint), 812
Azithromycin and warfarin interaction, 943
Azithromycin and warfarin, determination of the lack of a drug interaction between, 188

- B -

Bayesian data mining algorithm, application of an empiric, to reports of pancreatitis associated with atypical antipsychotics, 1122
Benzodiazepines, paradoxical reactions to, literature review and treatment options, 1177
Beta$_2$-agonists, focus on inhaled: efficacy, safety, and patient preference, 44s
Beta-lactamases, retrospective study of clinical outcomes with extended-spectrum—a different interpretation, 816
Blood pressure control and factors predicting control in a treatment-compliant male veteran population, 179
Blood pressure reduction is major determinant of risk, angiotensin-converting enzyme inhibitors and stroke, 1813
Board of Pharmaceutical Specialties–certified faculty: a survey of united states colleges of pharmacy, 395
Bone disorders associated with the human immunodeficiency virus: pathogenesis and management, 1331
Bridge therapy, a disease management protocol for outpatient perioperative, with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation, 649
Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results, 1524
Burkholderia cepacia lung exacerbation, empiric treatment of multidrug-resistant, in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy, 1641
Burn injuries, antifactor Xa levels in four patients with, who received enoxaparin to prevent venous thromboembolism, 1793

- C -

Calcitonin product, pharmacokinetics of modified oral, in healthy volunteers, 994
Cancer and non-Hodgkin's lymphoma, chemotherapy dose density in early-stage breast, 1347
Cancer chemotherapy, effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from, 488
Cancer, temozolomide in patients with advanced: phase I and pharmacokinetic study, 16
Candida kefyr, an uncommon but emerging fungal pathogen: report of two cases, 1084
Carbidopa-levodopa, apraxia of lid opening: dose-dependent response to, 401
Cardiac events, the use of antibiotics as secondary prevention for, 1652
Cardiac risk reduction program, impact of a, in vulnerable patients hospitalized with coronary artery disease, 768
Cardiology, unfractionated heparin in, redefining the standard of practice, 132s
Cardiovascular disease, development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of, 907
Carisoprodol withdrawal syndrome, 1804

Carvedilol for the treatment of portal hypertension, evaluation of, 94
Caspofungin: a potential cause of reversible severe thrombocytopenia, 1408
Cefazolin tolerance does not predict ceftriaxone hypersensitivity: unique side chains precipitate anaphylaxis, 668
Cefepime, treating serious infections: focus on, 216s
Ceftriaxone hypersensitivity, cefazolin tolerance does not predict: unique side chains precipitate anaphylaxis, 668
Central nervous system infections, meropenem administered as a prolonged infusion to treat serious gram-negative, 803
Cephalexin-induced acute tubular necrosis, 808
Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma, 1347
Chlamydia pneumoniae, macrolide therapy for, in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials, 338
Chlorpropamide, the effect of deinsuring, on the prescribing of oral antihyperglycemics for Nova Scotia seniors' pharmacare beneficiaries, 784
Cholesterol management in patients with diabetes mellitus, greater effect of enhanced pharmacist care on: a planned subgroup analysis of the study of cardiovascular risk intervention by pharmacists (SCRIP), 389
Chromonychia, fingernail clubbing and, associated with the use of angiotensin II receptor blockers, 546
Chronic obstructive pulmonary disease, 33s
Cisapride and troglitazone, impact of safety warnings on drug utilization: marketplace life span of, 978
Clinical pharmacists save thousands of lives: big decrease in dose-related adverse effects, 422
Clinical pharmacy and pharmaceutical care, 1499
Clinical pharmacy, pharmaceutical care, and the quality of drug therapy, 1491
Clopidogrel, role of, in unstable angina and non–ST segment elevation myocardial infarction: from literature and guidelines to practice, 1037
Clopidogrel-induced thrombotic thrombocytopenic purpura–hemolytic uremic syndrome after coronary artery stenting, 664
Clopidogrel-induced thrombotic thrombocytopenic purpura–hemolytic uremic syndrome after coronary artery stenting, 664
Clubbing, fingernail and chromonychia associated with the use of angiotensin II receptor blockers, 546
Cognitive services, pharmacist compensation for: focus on the physician office and community pharmacy, 372
Colchicine myotoxicity: case reports and literature review, 1784
Colony-stimulating factors, effects of indirect and additional direct costs on the risk threshold for prophylaxis with, in patients at risk for severe neutropenia from cancer chemotherapy, 488
Contrast media, metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous, 987
Core clinical pharmacy services in united states hospitals in 2020, evidence-based: services and staffing, 427
Core set of clinical pharmacy services in 2020, the feasibility of implementing an evidence-based: manpower, marketplace factors, and pharmacy leadership, 441
Coronary artery disease, drug-eluting stents: a mechanical and pharmacologic approach to, 1554
Coronary artery disease, impact of a cardiac risk reduction program in vulnerable patients hospitalized with, 768
Coronary artery disease, macrolide therapy for *Chlamydia pneumoniae* in the secondary prevention of: a meta-analysis of randomized controlled trials, 338
Coronary artery stenting, hemolytic uremic syndrome, clopidogrel-induced thrombotic thrombocytopenic purpura, after, 664
Correction, epidemiology and possible causes of autism, P-3
Cortisol suppression, lack of a fluoxetine effect on prednisolone disposition and, 482
Creatinine, elevations in serum concentration: concerning or reassuring?, 697
Critically ill patient, managing anemia in the, 229
Cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group, likelihood and mechanisms of, 854
Cyanide poisoning and its treatment, 1358
Cyclooxygenase 2–specific inhibitors, making progress in the management of postoperative pain: a review of the, 1714
Cystic fibrosis, empiric treatment of multidrug-resistant *Burkholderia cepacia* lung exacerbation in a patient with, application of pharmacodynamic concepts to meropenem therapy, 1641
Cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory, comparison of, 720
Cytomegalovirus disease in renal transplant recipients, efficacy and safety of low-dose valganciclovir for prevention of, a single-center, retrospective analysis, 1323

- D -

Daptomycin, critical review, 41
Darbepoetin alfa 200 µg every 2 weeks in both naïve patients and patients switched from epoetin alfa, evaluation of the US oncology network's recommended guidelines for therapeutic substitution with, 313
Dementia, donepezil for alcohol-related: a case report, 419
Depression, history of, as a predictor of adverse outcomes in patients hospitalized for decompensated heart failure, 1306
Device technology, better living through medical, 298
Diabetes insipidus, transient, after discontinuation of

therapeutic vasopressin, 541
Diabetes mellitus, delaying the onset of type 2, in patients with prediabetes, 362
Diabetes mellitus, focusing on patient-oriented evidence that matters in the care of patients with, 295
Diabetes mellitus, frequency of new-onset, and use of antipsychotic drugs among central Texas veterans, 1529
Diabetes mellitus, greater effect of enhanced pharmacist care on cholesterol management in patients with: a planned subgroup analysis of the study of cardiovascular risk intervention by pharmacists (SCRIP), 389
Diabetes mellitus, steroid-induced, and related risk factors in patients with neurologic diseases, 508
Diabetes mellitus, sulfonylurea treatment of type 2: focus on glimepiride, 606
Diabetes mellitus, the utility of insulin glargine in the treatment of, 736
Diabetes mellitus, type 2, in the pediatric population, 869
Diabetic dyslipidemia, pharmacologic treatment of type 2, 1692
Diabetic peripheral neuropathy, role of topiramate for the treatment of painful, 1186
Diarrhea, differences in rates of, in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir, 727
Didanosine and tenofovir disoproxil fumarate, fatal lactic acidosis associated with coadministration of, 1089
Didanosine tablets, magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered, 1539
Direct thrombin inhibitors, impact of oral, on anticoagulation clinics, 1204
Direct thrombin inhibitors, new developments in anticoagulation therapy: oral, 165s
Direct thrombin inhibitors, the role of oral, in atrial fibrillation, 190s
Direct thrombin inhibitors, the role of oral, in the prophylaxis of venous thromboembolism, 179s
Direct thrombin inhibitors, the role of oral, in the treatment of venous thromboembolism, 184s
Diuretic resistance, food: an unrecognized source of loop, 630
Divalproex, extended-release, sodium for mood stabilization, 1147
Donepezil for alcohol-related dementia: a case report, 419
Dopamine and norepinephrine, fixed-dose vasopressin compared with titrated, as initial vasopressor therapy for septic shock, 1002
Dose density, chemotherapy, in early-stage breast cancer and non-Hodgkin's lymphoma, 1347
Drug interactions, potential, with the percent carbohydrate-deficient transferrin (%CDT) test, a new alcohol biomarker, 829
Drug prescribing, potentially inappropriate, among first-visit elderly outpatients in taiwan, 846
Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease, 1554
Dyslipidemia, pharmacologic treatment of type 2 diabetic, 1692

- E -

Economics of antibiotic use policies, 232s
Editorial, blood, sweat, and tears: wasted by Medicare's missed opportunity, 1655
Encephalomyelitis, fatal acute, after a single dose of intrathecal methotrexate, 673
Energy expenditure in mechanically ventilated, critically ill patients, retrospective evaluation of commonly used equations to predict, 1659
Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection, 198
Enoxaparin, a disease management protocol for outpatient perioperative bridge therapy with, in patients requiring temporary interruption of long-term oral anticoagulation, 649
Enoxaparin, antifactor Xa levels in four patients with burn injuries who received, to prevent venous thromboembolism, 1793
Enterococcus faecalis resistant to linezolid: case series and review of the literature, 1225
Epoetin alfa, evaluation of the US oncology network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 µg every 2 weeks in both naïve patients and patients switched from, 313
Ethanol, intravenous, for the treatment of alcohol withdrawal syndrome in critically ill patients, 1578
Extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving quetiapine and paroxetine, 921

- F -

Factor Xa inhibition, introduction—current concepts in thrombosis management: focus on, 61s
Factor Xa inhibitors, evolving concepts in the treatment of venous thromboembolism: the role of, 82s
Febrile neutropenia, tobramycin pharmacokinetics in children with, undergoing stem cell transplantation: once-daily versus thrice-daily administration, 564
Feeding intolerance, enteral administration of naloxone for treatment of opioid-associated intragastric, 291
Fenoldopam for radiographic contrast material–induced nephropathy, 819
Ferric gluconate complex, single-dose pharmacokinetics of sodium, in iron-deficient subjects, 574
Fever, amifostine-induced: case report and review of the literature, 155
Fibromyalgia, benefit of ribose in a patient with, 1646
Fingernail clubbing and chromonychia associated with the use of angiotensin II receptor blockers, 546
Fluoxetine effect, lack of a, on prednisolone disposition and cortisol suppression, 482

Fluoxetine, acute and continuation treatment adequacy with venlafaxine extended release compared with, 33
Fluticasone metered-dose inhaler, in vitro performance characteristics of valved holding chamber and spacer devices with a, 159
Fluticasone propionate nasal spray, effect of, on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis, 26
Fluvastatin and review of the literature, oral anticoagulant drug interactions with statins: case report of, 285
Fondaparinux therapy, special considerations with, heparin-induced thrombocytopenia and wound healing, 88s
Food: an unrecognized source of loop diuretic resistance, 630
Fungal infections, changing strategies for the management of invasive, 4s
Fungal pathogen, *Candida kefyr*, an uncommon but emerging, report of two cases, 1084

- G -

Gastric pH and guaiac measurements, evaluation of, in neonates receiving acid suppression therapy during extracorporeal membrane oxygenation, 1130
Gastric pH, magnitude and duration of elevated, in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets, 1539
Gatifloxacin and glyburide therapy, severe and resistant hypoglycemia associated with concomitant, 924
Genotyping methods, comparison of cytochrome P450 2C9, and implications for the clinical laboratory, 720
Glimepiride, sulfonylurea treatment of type 2 diabetes mellitus: focus on, 606
Glyburide and gatifloxacin therapy, severe and resistant hypoglycemia associated with concomitant, 924
Grapefruit juice, influence of, on the systemic availability of itraconazole oral solution in healthy adult volunteers, 460
Guidelines and key articles in pharmacotherapeutic management of arrhythmias, 248
Guidelines and key articles relative to treatment of patients with acute coronary syndromes, 105

- H -

Haloperidol and tacrolimus administration in the critically ill patient, prolonged cardiac repolarization after, 404
Healthy people 2010: challenges, opportunities, and a call to action for America's pharmacists, an ACCP white paper, 1241
Heart failure due to right ventricular dysfunction, nesiritide for treatment of, 1236
Heart failure, anemia management in: a thick review of thin data, 757
Heart failure, angiotensin-converting enzyme inhibitor therapy in patients with, enrolled in a managed care organization: effect on costs and probability of hospitalization, 351
Heart failure, assessment of hypothyroidism in patients with chronic, 358
Heart failure, chronic–related interventions after starting rosiglitazone in patients receiving insulin, 1317
Heart failure, high-impact articles related to the pharmacotherapeutic management of systolic, 1594
Heart failure, history of depression as a predictor of adverse outcomes in patients hospitalized for decompensated, 1306
Heart failure, impact of nesiritide on health care resource utilization and complications in patients with decompensated, 1137
Heart failure, interaction between nesiritide and a heparin-coated pulmonary artery line during an infusion for decompensated, 1634
Heart failure, levosimendan, a new calcium-sensitizing inotrope for, 1366
Heart failure, tachycardia-induced, does not alter myocardial p-glycoprotein expression, 1
Hematuria, early evaluation of, in a patient receiving anticoagulant therapy and detection of malignancy, 1638
Hemodialysis, malnutrition in patients undergoing, is intradialytic parenteral nutrition the answer, 1748
Hemodynamic and analgesic effects of a single 7.5-mg intravenous dose of morphine in patients with moderate-to-severe postoperative pain, 1675
Heparin overview and issues, 103s
Heparin protocol based on sex, age, height, and weight, achieving target antifactor Xa activity with a, 713
Heparin standard, treatment of venous thromboembolism: challenging the unfractionated, 127s
Heparin, challenges in variation and responsiveness of unfractionated, 108s
Heparin, tenecteplase and unfractionated, potential in vitro interaction between, 1154
Heparin, unfractionated, a nursing dilemma, 156s
Heparin, unfractionated, dosing nomograms: road maps to where, 142s
Heparin, unfractionated, economics of, beyond acquisition cost, 161s
Heparin, unfractionated, focus on a high-alert drug, 146s
Heparin, unfractionated, in cardiology: redefining the standard of practice, 132s
Heparin-coated pulmonary artery line, interaction between nesiritide and a, during an infusion for decompensated heart failure, 1634
Heparin-induced thrombocytopenia and wound healing, special considerations with fondaparinux therapy, 88s
High-impact articles related to the pharmacotherapeutic management of systolic heart failure, 1594

High-performance liquid chromatography, evaluation of kidney function in patients with acute renal failure using: a case report, 145
HIV infection, atazanavir for the treatment of, 1732
HIV infection, enfuvirtide, a new fusion inhibitor for therapy of, 198
HIV infection, pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with, 453
HIV, differences in rates of diarrhea in patients with, receiving lopinavir-ritonavir or nelfinavir, 727
HIV, pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected, 307
HIV, sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with, 592
Holding chamber and spacer devices, in vitro performance characteristics of valved, with a fluticasone metered-dose inhaler, 159
Hormone replacement therapy, impact of the women's health initiative trial results on, 495
Hot flashes, nonhormonal alternatives for the treatment of, 79
Human immunodeficiency virus infection, atazanavir for the treatment of, 1732
Human immunodeficiency virus infection, enfuvirtide, a new fusion inhibitor for therapy of, 198
Human immunodeficiency virus, bone disorders associated with the, pathogenesis and management, 1331
Human immunodeficiency virus, magnitude and duration of elevated gastric pH in patients infected with, after administration of chewable, dispersible, buffered didanosine tablets, 1539
Hydromorphone hydrochloride, effect of fluticasone propionate nasal spray on bioavailability of intranasal, in patients with allergic rhinitis, 26
Hypercalcemia, pamidronate treatment for, in an infant receiving parenteral nutrition, 937
Hypercholesterolemia, cost of a pharmacist-directed intervention to increase treatment of, 1077
Hypertension management and control in primary care: a study of 20 practices in 14 states, 500
Hypertension, failure of computerized treatment suggestions to improve health outcomes of outpatients with uncomplicated, 324
Hypertension, key articles and guidelines in the management of, 1385
Hypertension, relationship between symptoms and health-related quality of life in patients treated for, 344
Hypoglycemia, fatal, associated with levofloxacin, 1807
Hypoglycemia, severe and resistant, associated with concomitant gatifloxacin and glyburide therapy, 924
Hypothyroidism, assessment of, in patients with chronic heart failure, 358

- I -

Ibuprofen and acetaminophen in children, the antipyretic effect of, 280
Imatinib mesylate and its metabolite CGP 74588 in humans, biliary excretion of, 1232
Imatinib mesylate, the influence of St. John's wort on the pharmacokinetics and protein binding of, 1508
Imipenem and meropenem, pharmacodynamics of, against Enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*, 8
Immunosuppressive strategies in renal transplantation, current and future, 1159
Infectious diseases pharmacotherapy, key references in, 1586
INR, effect of age on, at the time of major bleeding in patients treated with warfarin, 600
Insights from the Society of Infectious Diseases Pharmacists, 894
Insulin glargine and insulin aspart, intentional overdose with, 1412
Insulin glargine, the utility of, in the treatment of diabetes mellitus, 736
Interacting drugs, frequency of concurrent use of warfarin with potentially, 1668
International normalized ratio, effect of age on, at the time of major bleeding in patients treated with warfarin, 600
International normalized ratio, unreliability of, for monitoring warfarin therapy in patients with lupus anticoagulant, 836
Itraconazole oral solution, influence of grapefruit juice on the systemic availability of, in healthy adult volunteers, 460

- K -

Key articles and guidelines in pharmacotherapeutic management of arrhythmias, 248
Key articles and guidelines in the management of hypertension, 1385
Key articles and guidelines relative to treatment of patients with acute coronary syndromes, 105
Key references in infectious diseases pharmacotherapy, 1586
Kidney function, evaluation of, in patients with acute renal failure using high-performance liquid chromatography: a case report, 145

- L -

Lactic acidosis, fatal, associated with coadministration of didanosine and tenofovir disoproxil fumarate, 1089
Lamivudine, ritonavir, zidovudine, and stavudine, pharmacokinetic characteristics of, in children with human immunodeficiency virus infection, 453
Lepirudin, excessive anticoagulation and anaphylactic reaction after rechallenge with, in a patient with heparin-induced thrombocytopenia, 1800
Levodopa-carbidopa, apraxia of lid opening: dose-dependent response to, 401

Levofloxacin, fatal hypoglycemia associated with, 1807
Levosimendan, a new calcium-sensitizing inotrope for heart failure, 1366
Linezolid, *Enterococcus faecalis* resistant to, case series and review of the literature, 1225
Lipoprotein cholesterol level, low-density, a clinical comparison of calculated versus direct measurement of, 167
Liver dysfunction and renal failure, argatroban dosing in intensive care patients with acute, 409
Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature, 150
Liver toxicity and statins: a meta-analysis, 584
Lopinavir-ritonavir or nelfinavir, differences in rates of diarrhea in patients with human immunodeficiency virus receiving, 727
Low-density lipoprotein cholesterol level, a clinical comparison of calculated versus direct measurement of, 167
Lupus anticoagulant, unreliability of international normalized ratio for monitoring warfarin therapy in patients with, 836

- M -

Macrolide therapy for *Chlamydia pneumoniae* in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials, 338
Magnesium for the treatment and prevention of atrial tachyarrhythmias, 877
Malignancy, early evaluation of hematuria in a patient receiving anticoagulant therapy and detection of, 1638
Malnutrition in patients undergoing hemodialysis: is intradialytic parenteral nutrition the answer, 1748
Medicare's missed opportunity, editorial, blood, sweat, and tears: wasted by, 1655
Meperidine is alive and well in the new millennium: evaluation of meperidine usage patterns and frequency of adverse drug reactions, 776
Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections, 803
Meropenem and imipenem, pharmacodynamics of, against Enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*, 8
Meropenem therapy, empiric treatment of multidrug-resistant *Burkholderia cepacia* lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to, 1641
Mesenteric thrombosis and antithrombin deficiency, argatroban therapy for: case report and review of the literature, 659
Metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous contrast media, 987
Methadone enantiomers, pharmacokinetics and pharmacodynamics of, after coadministration with amprenavir in opioid-dependent subjects, 1110
Methadone, effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-, 970
Methemoglobinemia, critical rebound, after methylene blue treatment: case report, 538
Methionine, bioavailability and lack of toxicity of S-adenosyl-L-, (SAMe) in humans, 1501
Methotrexate, fatal acute encephalomyelitis after a single dose of intrathecal, 673
Methylene blue treatment, critical rebound methemoglobinemia after: case report, 538
Metoclopramide therapy, tacrolimus toxicity associated with concomitant, 532
Migraine headache misconceptions: barriers to effective care, 638
Monoamine oxidase type B inhibitor, tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible, 1295
Mood stabilization, extended-release divalproex sodium for, 1147
Morphine, analgesic and hemodynamic effects of a single 7.5-mg intravenous dose of, in patients with moderate-to-severe postoperative pain, 1675
Multidrug-resistant bacteria, oritavancin and tigecycline: investigational antimicrobials for, 58
Myocardial infarction, role of clopidogrel in unstable angina and non–ST segment elevation, from literature and guidelines to practice, 1037
Myocardial infarction, tegaserod-induced: case report and hypothesis, 526
Myocardial infarction, work-related outcomes after a, 1515
Myotoxicity, colchicines, case reports and literature review, 1784

- N -

Naloxone, enteral administration of, for treatment of opioid-associated intragastric feeding intolerance, 291
Nelfinavir or lopinavir-ritonavir, differences in rates of diarrhea in patients with human immunodeficiency virus receiving, 727
Nephrology, from dialysis outcomes quality initiative to kidney disease outcomes quality initiative: new clinical practice guidelines in, what the practicing pharmacist needs to know, 551
Nephropathy, fenoldopam for radiographic contrast material–induced, 819
Nephrotoxicity, tenofovir-related: case report and review of the literature, 415
Nesiritide and a heparin-coated pulmonary artery line, interaction between, during an infusion for decompensated heart failure, 1634
Nesiritide for treatment of heart failure due to right ventricular dysfunction, 1236
Nesiritide, impact of, on health care resource utilization and complications in patients with decompensated heart failure, 1137
Nested case-control study, pharmacoepidemiology II:

a novel approach in pharmacoepidemiologic research, 1105
Neurocognition effects and a neuroprotective hypothesis, implications for atypical antipsychotics in the treatment of schizophrenia, 1759
Neurologic diseases, steroid-induced diabetes mellitus and related risk factors in patients with, 508
Neuropathy, role of topiramate for the treatment of painful diabetic peripheral, 1186
Neuropathy, statin-associated peripheral, review of the literature, 1194
Neuroprotective hypothesis, neurocognition effects and, implications for atypical antipsychotics in the treatment of schizophrenia, 1759
Neutropenia, effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe, from cancer chemotherapy, 488
Nicotine-dependent adolescents, bupropion may support psychosocial treatment of, preliminary results, 1524
Nitrite abuse (poppers): epidemiology and clinical management of inhaled, 69
Nizatidine therapy, extrapyramidal symptoms related to adjunctive, in an adolescent receiving quetiapine and paroxetine, 921
Norepinephrine, fixed-dose vasopressin compared with titrated dopamine and, as initial vasopressor therapy for septic shock, 1002

- O -

Olanzapine and quetiapine, a retrospective analysis of the short-term effects of, on weight and body mass index in children and adolescents, 822
Ondansetron, relative bioavailability of an extemporaneous 4-mg capsule formulation versus solution, 477
Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria, 58
Orthopedic surgery, emerging options for thromboprophylaxis after, a review of clinical data, 66s
Orthopedic surgery, evidence for extended prophylaxis in the setting of, 73s
Osteoporosis screening and treatment in women with schizophrenia: a controlled study, 515
Overanticoagulation and underanticoagulation, frequency and causes of, in patients treated with warfarin, 1311
Oxymorphone extended release and its metabolites, pharmacokinetics and dose-proportionality of: results of a randomized crossover study, 468

- P -

Pain syndromes, treatment of, with venlafaxine, 621
Pamidronate in children and adolescents, effectiveness of pretreatment in decreasing adverse events associated with, 195
Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition, 937
Pancreatitis associated with atypical antipsychotics, application of an empiric Bayesian data mining algorithm to reports of, 1122
Paroxetine and quetiapine, extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving, 921
Patient decision aid, development and preliminary testing of a, to assist pharmaceutical care in the prevention of cardiovascular disease, 907
Pediatric population, type 2 diabetes mellitus in the, 869
Peginterferon alfa-2b–ribavirin therapy, follow-up of adverse drug reactions from, 1546
Percent carbohydrate-deficient transferrin (%CDT) test, potential drug interactions with the, a new alcohol biomarker, 829
Peripheral neuropathy, statin-associated, review of the literature, 1194
P-glycoprotein expression, tachycardia-induced heart failure does not alter myocardial, 1
Pharmaceutical care and clinical pharmacy, 1499
Pharmaceutical care, clinical pharmacy, and the quality of drug therapy, 1491
Pharmacist's role, severe acute respiratory syndrome (SARS): the, 705
Pharmacist-provided anticoagulation management in united states hospitals: death rates, length of stay, medicare charges, bleeding complications, and transfusions, 953
Pharmacists, clinical, save thousands of lives: big decrease in dose-related adverse effects, 422
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus, 307
Pharmacoepidemiologic study designs, pharmacoepidemiology I: a review of, 964
Pharmacoepidemiology II: the nested case-control study—a novel approach in pharmacoepidemiologic research, 1105
Pharmacotherapy goes online, 821
Pharmacovigilance in the 21st century: new systematic tools for an old problem, 1099
Pharmacy education redux, 682
Pharmacy education scope of practice disconnect, an individual perspective on the, 677
Pharmacy education, the future of: back to which basics?, 688
Pharmacy education: back to the basics?—an alternative viewpoint, 685
Pharmacy education: beyond the basics, 690
Poppers: epidemiology and clinical management of inhaled nitrite abuse, 69
Portal hypertension, evaluation of carvedilol for the treatment of, 94
Postoperative pain, making progress in the management of, a review of the cyclooxygenase 2–specific inhibitors, 1714
Potassium concentrations during spironolactone therapy for heart failure, racial differences in patients', 750

Prediabetes, delaying the onset of type 2 diabetes mellitus in patients with, 362
Prednisolone disposition and cortisol suppression, lack of a fluoxetine effect on, 482
Pruritus, liver function test abnormalities and, in a patient treated with atorvastatin: case report and review of the literature, 150
Pulmonary disease, chronic obstructive, 33s
Pulmonary edema, acute, caused by quinine, 1221

- Q -

Quality of life, adverse effects of atypical antipsychotic agents and their effects on, 841
Quetiapine and olanzapine, a retrospective analysis of the short-term effects of, on weight and body mass index in children and adolescents, 822
Quetiapine and paroxetine, extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving, 921
Quinine, acute pulmonary edema caused by, 1221

- R -

Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure, 750
Rasagiline, tolerability, safety, pharmacodynamics, and pharmacokinetics of, a potent, selective, and irreversible monoamine oxidase type B inhibitor, 1295
Renal failure and liver dysfunction, argatroban dosing in intensive care patients with acute, 409
Renal failure, evaluation of kidney function in patients with acute, using high-performance liquid chromatography: a case report, 145
Renal transplantation, current and future immunosuppressive strategies in, 1159
Resistance to antimicrobial agents: an update, 203s
Resistance, the impact of antibiotic management on, 224s
Respiratory syncytial virus pneumonia, treatment of, in a lung transplant recipient: case report and review of the literature, 930
Ribose, benefit of, in a patient with fibromyalgia, 1646
Ritonavir, sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose, in patients infected with human immunodeficiency virus type 1, 592
Ritonavir, zidovudine, lamivudine, and stavudine, pharmacokinetic characteristics of, in children with human immunodeficiency virus infection, 453
Ritonavir-lopinavir or nelfinavir, differences in rates of diarrhea in patients with human immunodeficiency virus receiving, 727
Role of clopidogrel in unstable angina and non–ST segment elevation myocardial infarction: from literature and guidelines to practice, 1037
Rosiglitazone in patients receiving insulin, chronic heart failure–related interventions after starting, 1317

- S -

Safety warnings, impact of, on drug utilization: marketplace life span of cisapride and troglitazone, 978
SAMe, bioavailability and lack of toxicity of S-adenosyl-L-methionine, in humans, 1501
Saquinavir soft-gelatin capsules, sex-related differences in the pharmacokinetics of once-daily, boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1, 592
SARS, severe acute respiratory syndrome: the pharmacist's role, 705
Schizophrenia, osteoporosis screening and treatment in women with: a controlled study, 515
Schizophrenia: neurocognition effects and a neuroprotective hypothesis, implications for atypical antipsychotics in the treatment of, 1759
Septic shock, fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for, 1002
Septic shock, the role of vasopressin in vasodilatory, 1050
Serious infections, treating, focus on cefepime, 216s
Serum creatinine levels, metformin monitoring and change in, in patients undergoing radiologic procedures involving administration of intravenous contrast media, 987
Severe acute respiratory syndrome (SARS): the pharmacist's role, 705
SIDP, antimicrobial stewardship programs as a means to optimize antimicrobial use, 894
Smoking-cessation program consisting of extensive counseling, pharmacotherapy, and office spirometry: results of a pilot project in a veterans administration medical center, 1400
Somnolence, excessive, from aripiprazole in a child, 522
Spacer devices, in vitro performance characteristics of valved holding chamber and, with a fluticasone metered-dose inhaler, 159
Spironolactone therapy for heart failure, racial differences in patients' potassium concentrations during, 750
St. John's wort, the influence of, on the pharmacokinetics and protein binding of imatinib mesylate, 1508
Statin-associated peripheral neuropathy: review of the literature, 1194
Statins and liver toxicity: a meta-analysis, 584
Statins, oral anticoagulant drug interactions with: case report of fluvastatin and review of the literature, 285
Stavudine, ritonavir, zidovudine, and lamivudine, pharmacokinetic characteristics of, in children with human immunodeficiency virus infection, 453
Stem cell transplantation, tobramycin pharmacokinetics in children with febrile neutropenia undergoing: once-daily versus thrice-daily administration, 564

Stents, drug-eluting: a mechanical and pharmacologic approach to coronary artery disease, 1554
Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases, 508
Streptokinase-induced, antibody-mediated platelet aggregation, inhibition of, with tirofiban after exposure to streptokinase or streptococcal infection, 558
Stroke risk, angiotensin-converting enzyme inhibitors and, benefit beyond blood pressure reduction, 1064
Stroke, angiotensin-converting enzyme inhibitors and, blood pressure reduction is major determinant of risk, 1813
Sulfonamide antibiotics and other drugs containing a sulfonamide functional group, likelihood and mechanisms of cross-allergenicity between, 854
Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride, 606

- T -

Tacrolimus and haloperidol administration in the critically ill patient, prolonged cardiac repolarization after, 404
Tacrolimus toxicity associated with concomitant metoclopramide therapy, 532
Tegaserod-induced myocardial infarction: case report and hypothesis, 526
Tegaserod-induced myocardial infarction: case report and hypothesis—an alternative viewpoint, 1649
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study, 16
Tenecteplase and unfractionated heparin, potential in vitro interaction between, 1154
Tenofovir disoproxil fumarate and didanosine and, fatal lactic acidosis associated with coadministration of, 1089
Tenofovir disoproxil fumarate, effect of, on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone, 970
Tenofovir-related nephrotoxicity: case report and review of the literature, 415
Thrombin inhibitors, transitioning from traditional to novel anticoagulants: the impact of oral direct, on anticoagulation management, 199s
Thrombocytopenia and wound healing, special considerations with fondaparinux therapy: heparin-induced, 88s
Thrombocytopenia, caspofungin: a potential cause of reversible severe, 1408
Thromboembolism, evolving concepts in the treatment of venous, the role of factor Xa inhibitors, 82s
Thromboembolism, the role of oral direct thrombin inhibitors in the prophylaxis of venous, 179s
Thromboembolism, the role of oral direct thrombin inhibitors in the treatment of venous, 184s
Thromboembolism, treatment of venous, challenging the unfractionated heparin standard, 127s
Thromboprophylaxis, emerging options for, after orthopedic surgery: a review of clinical data, 66s
Thrombosis management, introduction—current concepts in, focus on factor Xa inhibition, 61s
Thrombosis management, pharmacoeconomics of, 95s
Thrombotic thrombocytopenic purpura–hemolytic uremic syndrome, clopidogrel-induced, after coronary artery stenting, 664
Tigecycline and oritavancin: investigational antimicrobials for multidrug-resistant bacteria, 58
Tirofiban, inhibition of streptokinase-induced, antibody-mediated platelet aggregation with, after exposure to streptokinase or streptococcal infection, 558
Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration, 564
Topiramate, role of, for the treatment of painful diabetic peripheral neuropathy, 1186
Transfusion trigger: a careless term that disregards pathophysiology, 948
Troglitazone and cisapride, impact of safety warnings on drug utilization: marketplace life span of, 978

- U -

Underanticoagulation, frequency and causes of overanticoagulation and, in patients treated with warfarin, 1311
Unfractionated heparin dosing nomograms: road maps to where, 142s
Unfractionated heparin in cardiology: redefining the standard of practice, 132s
Unfractionated heparin standard, treatment of venous thromboembolism: challenging the, 127s
Unfractionated heparin, challenges in variation and responsiveness of, 108s
Unfractionated heparin, dosing of, in acute coronary syndromes, 1681
Unfractionated heparin, economics of, beyond acquisition cost, 161s
Unfractionated heparin: a nursing dilemma, 156s
Unfractionated heparin: focus on a high-alert drug, 146s

- V -

Valganciclovir, efficacy and safety of low-dose, for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis, 1323
Vasopressin, fixed-dose, compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock, 1002
Vasopressin, the role of, in vasodilatory septic shock, 1050
Vasopressin, transient diabetes insipidus after discontinuation of therapeutic, 541
Venlafaxine extended release, acute and continuation treatment adequacy with, compared with fluoxetine, 33
Venlafaxine therapy, elevated defibrillation threshold with, 1095
Venlafaxine, treatment of pain syndromes with, 621

Visual disturbances, alendronate-induced auditory hallucinations and, 799
Vitamin K_1 for rapid anticoagulation reversal, impaired warfarin response secondary to high-dose, case series and literature review, 1213

- W -

Warfarin and azithromycin interaction, 943
Warfarin and azithromycin, determination of the lack of a drug interaction between, 188
Warfarin response, impaired, secondary to high-dose vitamin K_1 for rapid anticoagulation reversal: case series and literature review, 1213
Warfarin therapy in patients with lupus anticoagulant, unreliability of international normalized ratio for monitoring, 836
Warfarin, effect of age on international normalized ratio at the time of major bleeding in patients treated with, 600
Warfarin, frequency and causes of overanticoagulation and underanticoagulation in patients treated with, 1311
Warfarin, frequency of concurrent use of, with potentially interacting drugs, 1668
Weber effect, replication of the, using postmarketing adverse event reports voluntarily submitted to the united states food and drug administration, 743
Women's health initiative trial results, impact of the, on hormone replacement therapy, 495
Work-related outcomes after a myocardial infarction, 1515

- X, Z -

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics, 169s
Zidovudine 600 mg once/day versus 300 mg twice/day, pharmacodynamic effects of, in therapy-naïve patients infected with human immunodeficiency virus, 307
Zidovudine, lamivudine, ritonavir, and stavudine, pharmacokinetic characteristics of, in children with human immunodeficiency virus infection, 453

CORRECTION

The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

Patrick Smith, Pharm.D.

(Pharmacotherapy 2004;24(11):1508–1514)

The following authors should have been listed in the byline: Patrick F. Smith, Pharm.D., Julie M. Bullock, Pharm.D., Brent M. Booker, Pharm.D., Curtis E. Haas, Pharm.D., Charles S. Berenson, M.D., and William J. Jusko, Ph.D. We sincerely apologize to our readers for any misunderstanding that this error may have caused.